OLMA
Olema Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.82
−0.81%Aug 13, 2026, 00:00 UTC
Olema Pharmaceuticals appointed Jason O'Byrne as Chief Financial Officer, principal financial officer and principal accounting officer, effective as of the announcement date.
Aug 11, 2026, 18:27 UTC
Olema Pharmaceuticals completed enrollment in its pivotal Phase 3 OPERA-01 trial for breast cancer treatment, with top-line data expected in Q1 2027.
Source: